Ligand Pharmaceuticals IncorporatedLGNDNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+15.1%
5Y CAGR+17.5%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+15.1%/yr
vs +14.6%/yr prior
5Y CAGR
+17.5%/yr
Consistent
Acceleration
+0.5pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.2x
Strong expansion
Streak
2 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $214.30M | +19.9% |
| 2024 | $178.66M | +111.9% |
| 2023 | $84.32M | -39.9% |
| 2022 | $140.38M | +85.9% |
| 2021 | $75.52M | -21.0% |
| 2020 | $95.64M | +113.7% |
| 2019 | $-698.14M | -957.8% |
| 2018 | $81.39M | +20.3% |
| 2017 | $67.66M | +15.7% |
| 2016 | $58.48M | - |